Viktor P. Stus

机构：Centre for Cancer Biology · ORCID：0000-0002-4539-8126

发表论文 81 篇 · 总被引 7149 次 · h-index 19

代表论文

• Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial (2020 · The Lancet Oncology · 被引 764)
• RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections (2019 · Clinical Infectious Diseases · 被引 425)
• Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (2023 · Journal of Clinical Oncology · 被引 349)
• Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial (2023 · The Lancet Oncology · 被引 159)
• Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study (2023 · European Urology · 被引 147)
• Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial (2021 · European Heart Journal · 被引 122)